A Noninfectious Simian/Human Immunodeficiency Virus DNA Vaccine That Protects Macaques against AIDS
Open Access
- 15 March 2005
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 79 (6) , 3419-3428
- https://doi.org/10.1128/jvi.79.6.3419-3428.2005
Abstract
Simian/human immunodeficiency virus SHIV KU2 replicates with extremely high titers in macaques. In order to determine whether the DNA of the viral genome could be used as a vaccine if the DNA were rendered noninfectious, we deleted the reverse transcriptase gene from SHIV KU2 and inserted this DNA (Δ rt SHIV KU2 ) into a plasmid that was then used to test gene expression and immunogenicity. Transfection of Jurkat and human embryonic kidney epithelial (HEK 293) cells with the DNA resulted in production of all of the major viral proteins and their precursors and transient export of a large quantity of the Gag p27 into the supernatant fluid. As expected, no infectious virus was produced in these cultures. Four macaques were injected intradermally with 2 mg of the DNA at 0, 8, and 18 weeks. The animals developed neutralizing antibodies and low enzyme-linked immunospot assay (E-SPOT) titers against SHIV KU2 . These four animals and two unvaccinated control animals were then challenged with heterologous SHIV89.6P administered into their rectums. The two control animals developed viral RNA titers exceeding 10 6 copies/ml of plasma, and these titers were accompanied by the loss of CD4 + T cells by 2 weeks after challenge. The two control animals died at weeks 8 and 16, respectively. All four of the immunized animals became infected with the challenge virus but developed lower titers of viral RNA in plasma than the control animals, and the titers decreased over time in three of the four macaques. The fourth animal remained viremic and died at week 47. Whereas the control animals failed to develop E-SPOT responses, all four of the immunized animals developed anamnestic E-SPOT responses after challenge. The animal that died developed the highest E-SPOT response and was the only one that produced neutralizing antibodies against the challenge virus. These results established that noninfectious DNA of pathogenic SHIV could be used as a vaccine to prevent AIDS, even though the immunological assays used did not predict the manner in which the challenge virus would replicate in the vaccinated animals.Keywords
This publication has 65 references indexed in Scilit:
- HIV‐1 Nef equips dendritic cells to reduce survival and function of CD8+T cells: a mechanism of immune evasionThe FASEB Journal, 2004
- Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag GeneJournal of Virology, 2003
- Increased Mucosal Transmission but Not Enhanced Pathogenicity of the CCR5-Tropic, Simian AIDS-Inducing Simian/Human Immunodeficiency Virus SHIV SF162P3 Maps to Envelope gp120Journal of Virology, 2003
- Direct Binding of Human Immunodeficiency Virus Type 1 Nef to the Major Histocompatibility Complex Class I (MHC-I) Cytoplasmic Tail Disrupts MHC-I TraffickingJournal of Virology, 2002
- Multiple Effector Functions Mediated by Human Immunodeficiency Virus-Specific CD4+T-Cell ClonesJournal of Virology, 2001
- Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA VaccineScience, 2001
- Sensitive and Robust One-Tube Real-Time Reverse Transcriptase-Polymerase Chain Reaction to Quantify SIV RNA Load: Comparison of One- versus Two-Enzyme SystemsAIDS Research and Human Retroviruses, 2000
- A model for the maturation of protective antibody responses to SIV envelope proteins in experimentally immunized monkeysJournal of Medical Primatology, 1997
- Protective Effects of a Live Attenuated SIV Vaccine with a Deletion in the nef GeneScience, 1992
- Genetic immunization is a simple method for eliciting an immune responseNature, 1992